Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    No significant changes detected between the old and new screenshots; the page content and structure remain focused on the study details.
    Difference
    0.4%
    Check dated 2025-11-03T13:51:43.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    30 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    3%
    Check dated 2025-10-06T04:35:49.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    Updated the page version from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T01:27:16.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Added: Last Update Posted (Estimated) and Revision: v3.0.2; Deleted: Last Update Posted, Revision: v3.0.1, and Back to Top. This indicates the page now reports an estimated update time and uses a newer version, with a minor removal of a navigation element.
    Difference
    0.2%
    Check dated 2025-09-14T18:44:52.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The webpage has updated its version from v3.0.0 to v3.0.1 and has removed outdated dates from March and April 2025, replacing them with new dates in September 2025.
    Difference
    0.7%
    Check dated 2025-09-07T13:10:57.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has added a facility name and location related to skin and connective tissue diseases, along with the mention of pembrolizumab, while removing various location details and specific disease-related resources.
    Difference
    2%
    Check dated 2025-08-31T05:38:41.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.